The company has not filed an annual or quarterly report since its Q1 FY2022 10-Q, filed May 10, 2022. Its latest SEC filing is a SC 13G/A from Feb 10, 2023.
10-Q for Q1 FY2022, filed May 10, 2022
The sections below describe the company as of the FY2021 annual report.
Develops, manufactures and sells specialty medicines and drug-delivery devices, including auto-injectors, for patients and pharmaceutical partners.
10-K for FY2021, filed Mar 3, 2022Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a specialty pharmaceutical company focused primarily on the…View ↗
Our FDA-approved products include XYOSTED® (testosterone enanthate) injection; OTREXUP® (methotrexate) injection, which was sold to Otter…View ↗
Our strategy is to grow the business through targeted investments in internal and partnered product development and other corporate…View ↗
Antares sells its medicines and supplies devices or finished products to partners; partners pay for devices or shipped products and royalties tied to sales, while Antares also earns licensing and development revenue and shares Sumatriptan net profits with Teva.
10-K for FY2021, filed Mar 3, 2022We market and sell in the U.S. our proprietary product XYOSTED® (testosterone enanthate) injection for subcutaneous administration of…View ↗
Epinephrine Injection USP – We are the exclusive supplier of the device used in Teva’s epinephrine injection product. We receive payment…View ↗
Sumatriptan Injection USP – We are the exclusive supplier of the product containing sumatriptan which is commercialized by Teva. We are…View ↗
Teriparatide Injection – We are the exclusive supplier of the pen injection device used in Teva’s Teriparatide Injection product outside…View ↗
We disaggregate our revenue by type of goods and services and customer location.View ↗
10-K for FY2021, filed Mar 3, 2022
FY2021 revenue by product or service ↗$184M
10-K for FY2021, filed Mar 4, 2022
$184M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales, net
Sold outright
10-K for FY2021, filed Mar 3, 2022 |
69%
FY2018: 75%
|
Product sales, net, FY2021
$126.7M Sources
|
Sold outright |
|
Licensing and development revenue
|
11%
FY2018: 11%
|
Licensing and development revenue, FY2021
$19.6M Sources
|
|
|
Royalties
Licensed
10-K for FY2021, filed Mar 3, 2022 |
20%
FY2018: 14%
|
Royalties, FY2021
$37.7M Sources
|
Licensed |
Antares markets its own medicines in the U.S.; pharmaceutical partners such as Teva and Covis handle distribution of partnered products, which move through pharmacies and distributors to healthcare providers and hospitals.
10-K for FY2021, filed Mar 3, 2022We market and sell in the U.S. our proprietary product XYOSTED® (testosterone enanthate) injection for subcutaneous administration of…View ↗
Epinephrine Injection USP – We are the exclusive supplier of the device used in Teva’s epinephrine injection product. We receive payment…View ↗
Makena® Subcutaneous Auto Injector – We are the exclusive supplier of the device used in the Makena® subcutaneous auto injector. We receive…View ↗
Teriparatide Injection – We are the exclusive supplier of the pen injection device used in Teva’s Teriparatide Injection product outside…View ↗
Yes. It kept 25 cents of every revenue dollar as net income in FY2021 and turned 16 cents into free cash flow.
10-K for FY2021, filed Mar 4, 2022
$65.9MView ↗
10-K for FY2021, filed Mar 4, 2022
$46.3MView ↗
10-K for FY2021, filed Mar 4, 2022
$30MView ↗
10-Q for Q1 FY2022, filed May 11, 2022
−$2.3MView ↗
10-Q for Q1 FY2022, filed May 10, 2022
Open tableView ↗
8-K, filed May 24, 2022
In connection with the consummation of the Merger, on May 24, 2022, the Company repaid in full all amounts outstanding and terminated its…View ↗
8-K, filed Apr 13, 2022
On April 12, 2022, Antares Pharma, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger…View ↗
Grew. Revenue grew 3.4x in 4 years, from $54.5M in FY2017 to $184M in FY2021, about 36% a year.
Beyond injectable therapies
The older report centers on self-administered injectable medicines and injection devices. The later description also includes oral and sublingual medicines and says the company explores opportunities beyond injections.
10-K for FY2018, filed Mar 12, 2019 10-K for FY2021, filed Mar 3, 2022Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a combination drug device company focused primarily on the…View ↗
Historically, our focus has been primarily the market for self-administered injectable drugs. We identify development and commercialization…View ↗
We market and sell NOCDURNA® (desmopressin acetate) in the U.S., which is the first and only sublingual tablet indicated for the treatment…View ↗
In October 2021, we entered into an exclusive license agreement (the “TLANDO® License Agreement”) with Lipocine for the product TLANDO®…View ↗
OTREXUP becomes a partnered product
The older report lists OTREXUP as a proprietary marketed product. The later report says Antares sold product assets to Otter and continues making and supplying the product as a partner.
10-K for FY2018, filed Mar 12, 2019 10-K for FY2021, filed Mar 3, 2022In addition to these significant achievements in 2018, we continue to market and sell our proprietary product OTREXUP® (methotrexate)…View ↗
In December 2021, we sold certain assets used in the operation of the OTREXUP® product to Otter under an Asset Purchase Agreement for a…View ↗
Competes with AbbVie, Perrigo, Eli Lilly, Endo, Allergan, Pfizer, Actavis, Sandoz, Viatris, Teva, Clarus, Marius Pharmaceuticals, Medexus Pharma, Cumberland Pharmaceuticals, Hospira, and Accord Healthcare
10-K for FY2021, filed Mar 3, 2022Competition in the U.S. testosterone replacement market includes transdermal solutions such as AbbVie’s Androgel® 1% and 1.62%, Perrigo’s…View ↗
Loading...
